Phase value assessment reveals iron accumulation in parkinson disease

PD is characterized by iron accumulation in the substantia nigra (SN) different from healthy controls. We aim to quantify iron accumulation via susceptibility weighted imaging (SWI) in Parkinson disease (PD). Twenty patients with PD and 21 healthy controls were included in this study. The SWI phase value was evaluated from SN in two areas (middle midbrain and lateral side of middle midbrain) at the axial plane for both sides (right and left). The PD group was divided into two subgroups after clinical examination: the affected side (AS), which was the contralateral of the clinically prominent side and the non-affected side (NAS). The subgroups were analyzed individually. The results of both sides compared between the PD and control groups, as well as between the PD subgroups. The phase values were statistically different in the PD-AS and control group in both areas (< 0.001). Furthermore, at the middle midbrain, the PD-NAS showed a statistical difference compared with the control group (p=0.002). Within the PD groups, only the lateral side of the middle midbrain area (LMMA) demonstrated a statistical difference between the AS and NAS subgroups (p = 0.005). Phase value assessment is useful to demonstrate the effect of iron accumulation on substantia nigra in PD.

PDF

___

1. Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124:901-8.

2. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114:2283-5.

3. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain. 1999;122:1421-8.

4. Liu Y, Wang G, Zhao L et al. SWI phase asymmetries in deep gray matter of healthy adults: is there an association with handedness? Brain Imaging Behav. 2013;7:220-2.

5. Thomas M, Jankovic J. Neurodegenerative disease and iron storage in the brain. Curr Opin Neurol. 2004;17:334-7.

6. Berg D, Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov Disord. 2006;21:1299.

7. Haacke EM, Xu Y, Cheng YC, Reichenbach JR. Susceptibility weighted imaging (SWI). Magn Reson Med. 2004;52:612-3.

8. Haacke EM, Ayaz M, Khan A et al. Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain. J Magn Reson Imaging. 2007;26:252-6.

9. Wallis LI, Paley MN, Graham JM et al. MRI assessment of basal ganglia iron deposition in Parkinson’s disease. J Magn Reson Imaging. 2008;28:1061-5.

10. Martin-Bastida A, Lao-Kaim NP, Loane C, et al. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson’s disease: a crosssectional study of iron-related magnetic resonance imaging susceptibility. Eur J Neurol. 2017;24:352-7.

11. Gerlach M, Double KL, Ben-Shachar D, et al. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson’s disease. Neurotox Res. 2003;5:32-5.

12. Reimão S, Pita Lobo P, Neutel D et al. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson’s disease patients. Eur J Neurol. 2015;22:540-3.

13. Ohtsuka C, Sasaki M, Konno K et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord. 2014;20:755-7.

14. Baudrexel S, Nürnberger L, Rüb U et al. Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson’s disease. Neuroimage. 2010;51:512-20.

15. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain. 1999;122:1437-8.

16. Schwarz ST, Afzal M, Morgan PS, et al. The ‘swallow tail’ appearance of the healthy nigrosome - a new accuratetest of Parkinson’s disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One. 2014;9:93814.

17. Gramsch C, Reuter I, Kraff O et al. Nigrosome 1 visibility at susceptibility weighted 7T MRI-A dependable diagnostic marker for Parkinson’s disease or merely an inconsistent, age-dependent imaging finding? PLoS One. 2017;12:0185489.

18. Gao P, Zhou PY, Li G et al. Visualition of nigrosomes-1 in 3T MR susceptibility weighted imaging and its absence in diagnosing Parkinson’s disease. Eur Rev Med Pharmacol Sci. 2015;19:4603-23.

19. Zhang J, Zhang Y, Wang J et al. Characterizing iron deposition in Parkinson’s disease using susceptibility-weighted imaging: an in vivo MR study. Brain Res. 2010;12:1324-30.

20. Azuma M, Hirai T, Yamada K et al. Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility Mapping. Am J Neuroradiol. 2016;37:782-5.

21. Liu Y, Wang G, Zhao L et al. SWI phase asymmetries in deep gray matter of healthy adults: is there an association with handedness? Brain Imaging Behav. 2013;7:220-2.